SUBSCRIBE
SUBSCRIBE

Cancer

Katherine Welles
Drug Development
Merck’s Keytruda Fails in Late-Stage HCC Trial
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial.
February 20, 2019
 · 
2 min read
 · 
Alex Keown
BioCapital
When Chemo and Surgery Fails, Targeted Radiation Is an Option for Kids With Liver Cancer
Luckily, primary malignant liver tumors in children are rare. They account for only 1 to 2 percent of all childhood cancers. The most common treatment is surgery and chemotherapy. However, not all can be treated by surgery and sometimes they do not respond to chemotherapy.
November 8, 2018
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
China’s First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent’s TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
December 25, 2025
 · 
11 min read
Press Releases
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug ‘SNB-101' on Gastric Cancer.
December 24, 2025
 · 
3 min read
Press Releases
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic
December 24, 2025
 · 
3 min read
Press Releases
Singlera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection Products
December 24, 2025
 · 
2 min read
Press Releases
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
December 24, 2025
 · 
8 min read
Press Releases
Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
December 24, 2025
 · 
1 min read
Press Releases
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
December 24, 2025
 · 
2 min read
Press Releases
Health Canada Approves TEVIMBRA® (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma
December 24, 2025
 · 
10 min read
Press Releases
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
December 24, 2025
 · 
4 min read
Press Releases
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
December 24, 2025
 · 
4 min read
Press Releases
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
December 24, 2025
 · 
4 min read
Press Releases
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
December 23, 2025
 · 
3 min read
Press Releases
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
December 23, 2025
 · 
14 min read
Press Releases
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
December 23, 2025
 · 
3 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
December 23, 2025
 · 
19 min read
Press Releases
Promontory Therapeutics Announces Interim Efficacy Requirement Reached on Phase 2 Study of PT-112 Monotherapy in Patients with Recurrent Thymoma
December 23, 2025
 · 
4 min read
Press Releases
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
December 23, 2025
 · 
4 min read
Press Releases
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
December 23, 2025
 · 
9 min read
Press Releases
Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer
December 23, 2025
 · 
4 min read
Press Releases
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
December 23, 2025
 · 
7 min read
Load More